Antiretroviral drugs in HIV infection

Indian Journal of Pharmacology

Volumn 31, Issue 2, 1999, Pages 96-103

  Vajpayee, Madhu ^a   Dar, Lalit ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antiretroviral drug; Human immunodeficiency virus

Indexed keywords

ABACAVIR; ADEFOVIR; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; CARBAMAZEPINE; CLARITHROMYCIN; DELAVIRDINE; DIDANOSINE; HYDROXYETHOXYMETHYLPHENYLTHIOTHYMINE; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PHENOBARBITAL; PHENYTOIN; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TERT BUTYL DIMETYLSILYLAMINOOXATHIOLE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; ASTHENIA; BLOOD TOXICITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESISTANCE; FATIGUE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYALGIA; NEPHROLITHIASIS; ORAL DRUG ADMINISTRATION; PANCREATITIS; PERIPHERAL NEUROPATHY; RASH; TASTE DISORDER; VIRUS REPLICATION;

EID: 0032908551     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995;267:483-9.
2. de Clercq E. Antiviral therapy for human immunodeficiency vrus infections. Clin Microbiol Rev 1995;8:200-39.
3. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after sero conversion. Ann Intern Med 1995;122:573-9.
4. Yarchoan R, Mitsuya H, Meyers CE, et al. Clinical pharmacology of 3′ azido-2′,3′ - dideoxythyimidine (zidovudine) and related dideoxy-nucleosides. N Engl J Med 1989;321:726-38.
5. St.Clair MH, Richards CA, Spector T, et al. 3-azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodefciency virus rever setranscriptase. Antimicrob Agents Chemother 1987;31:1972-7.
6. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-azido - 3′-deoxythymidine (BWA509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type-III/lymphadenopathy associated virus in vitro. Proc Natl Acad Sci USA 1985;82:7096-100,
7. Meleod GK, Hammer SM. Zidovudine: five years later. Ann Intern Med 1992;117:487-501.
8. Nadler JP. Early initiation of antiretroviral therapy for infaction with human immunodeficiency virus: considerations in 1996. Clin Infect Dis 1996;23:227-30.
9. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex - a double bund, placebo-controlled trial. N Engl J Med 1987;317:185-91.
10. Fischl MA, Parker CB, Pettinelli C, et al. A randomised controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodefeciency syndrome. N Engl J Med 1990;323:1009-14.
11. Concorde Coordinating Committee. Concorde:MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
12. McKinney RE Jr, Maha MA, Conner EM et al. A multicentertrial of oral zidovudine in children with advanced immunodeficeincy virus disease. N Engl J Med 1991;324: 1018-25.
13. Pitt J, Cotton D. Treating the HIV infected pregnant woman and her child. AIDS Clin Care 1997;9:91-5.
14. Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993;325:1686-1695.
15. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase conferhigh level resistance to zidovudine (AZT) Science 1989;246:1155-8.
16. Richman DD, Grimes JM, Lagakos SW. Effects of stage of disease and drug dose on zidovudine susceptibilites of isolates of human immunodefeciency virus. J AIDS 1990;3:743-6.
17. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-4.
18. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidavudine with didanosine in human immunodeficiency virus infection. New Engl J Med 1992;327:581-7.
19. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993;119:786-93.
20. Eron JJ, Chow Y-K, Caliendo AM, et al. Pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother 1993;37:1480-7.
21. Gu Z, Gao Q, Li X, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′, 3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992;166:7128-35.
22. Zhang D, Caliendo AM, Eron JJ, et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of human immunodefieciency virus type I reverse transcriptase. Antimicrob Agents Chemother 1994;38:282-7.
23. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodefieciency virus infection. N Engl J Med 1994;330:657-62.
24. Fitzgibbon JE, Howell RE, Haberzettl CA, et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′, 3′-dideoxycytidine. Antimicrob Agents Chemother 1992;36:153-7.
25. Lea AP, Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996;51:846-64.
26. Browne MJ, Mayer KH, Chafee SBD, et al. 2′,3′didehydro3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993;167:21-9.
27. D'Aquila RT. HIV-1 drug resistance: Molecular pathogenesis and laboratory monitoring. In : Pomerantz R, ed. Clinics in laboratory medicine, vol 14. Philadelphia: WB Saunders Co, 1994; 1-30.
28. Cammack N, Rouse P, Marr CLP, et al. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 1992;43:2059-64.
29. Soudeyns H, Yao X-J, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991; 35:1386-90.
30. de Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997;10:674-93.
31. Holtzer CD, Coleman RL. Use of non-nucleoside reverse transcriptase inhibitors. Am J Health Syst Pharm 1998;55: 283-7.
32. Havlir DV, Lange JM. New antiretrovirals and new combinations. AIDS 1998;12 Suppl A:165-74.
33. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4689-90.
34. McQuade TJ, Tomasseli AQ, Liu L, et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrest HIV-like particle maturation. Science 1990;247:454-6.
35. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-17.
36. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996;173:1379-87.
37. Danner SA, Carr A, Leonard JM, et al. A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV protease. N Engl J Med 1995;333:1528-33.
38. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV-1 protease confers resistance to ritonavir. Nat Med 1996;2:760-6.
39. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors. JAMA 1997;227:145-53.
40. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996;70:8270-6.
41. Perry CM, Benfield P. Nelfinavir. Drugs 1997;54:81-7.
42. Caliendo AM, Hirsch MS. Combination therapy for infection due to human immunodeficiency virus type-1. Clin Infec Dis 1994;18:516-24.
43. Threlkeld S, Hirsch MS. Antiretroviral therapy. Med Clin North Am 1996;80:1263-79.
44. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-6.
45. Ho DD. Time to hit HIV: early and hard. N Engl J Med 1995;333:450-1.